摘要
Objective： To assess whether the polymorphism of ERCC1 Asn118Asn （C → T） had effects on cancer response to chemotherapy and outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimen for advanced colorectal cancer. Methods： ERCC1 Asn 118Asn polymorphism was analyzed in 99 patients with stages Ⅲ and Ⅳ advanced colorectal cancer treated with oxaliplatin-based chemotherapy, For all of the patients, ERCC1 Asnl18Asn genotype was analyzed for associations with treatment response and time to disease progress （TTP）. Results： The allele frequencies of the ERCC1 gene codon 118 were C/C 50.51% （50/99）, C/T 41.41% （41/99）, T/T 8.08% （8/99）, respectively. Patients with C/C genotype showed higher response rate than those with C/T ＋ T/T （OR = 3.764, 95% CI： 1.310-10.813）. The median TTP of all patients was 7 months （95% CI： 5.569--8.431）. Patients with C/C genotype showed a median TTP of 10 months （95% CI： 8.924-11.076）, which was longer than 5 months （95% CI： 4.424-5.576） in patients with C/T ＋ T/T genotypes. Conclusion： Our results showed a link between ERCC1 Asn118Asn genetic polymorphism and cancer response to oxaliplatin-based chemotherapy and time to disease progress in Chinese patients with advanced colorectal cancer. ERCC1 Asn 118Asn genotyping may be of predictive benefit in selecting treatment regimen for advanced colorectal cancer.
